Precision medicine in colorectal cancer

Evolving genomic landscape and emerging consensus

Kurt W. Fisher, Antonio Lopez-Beltran, Rodolfo Montironi, Liang Cheng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Colorectal cancer is the third most lethal cancer in men and women in the USA. Although surgical resection is the mainstay of treatment, many patients develop local and widely metastatic disease and become resistant to conventional chemotherapeutics. Recent comprehensive molecular characterization has led to subclassification of colorectal adenocarcinoma based on molecular properties, such as microsatellite instability and high CpG island methylation. These emerging subclassifications are associate with varying frequencies of RAS, BRAF, APC and other genetic events and have the ability to redefine therapeutic regimens. In this review, we examine how molecular diagnostics are currently used while providing insight into emerging implications for molecular analysis for personalized therapy in colorectal cancer.

Original languageEnglish (US)
Pages (from-to)2711-2719
Number of pages9
JournalFuture Oncology
Volume11
Issue number19
DOIs
StatePublished - Oct 1 2015

Fingerprint

Precision Medicine
Colorectal Neoplasms
Microsatellite Instability
CpG Islands
Molecular Pathology
Methylation
Adenocarcinoma
Therapeutics
Neoplasms

Keywords

  • BRAF
  • colorectal cancer
  • KRAS
  • microsatellite instability
  • molecular diagnostics
  • NRAS
  • personalized medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Precision medicine in colorectal cancer : Evolving genomic landscape and emerging consensus. / Fisher, Kurt W.; Lopez-Beltran, Antonio; Montironi, Rodolfo; Cheng, Liang.

In: Future Oncology, Vol. 11, No. 19, 01.10.2015, p. 2711-2719.

Research output: Contribution to journalArticle

Fisher, Kurt W. ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Cheng, Liang. / Precision medicine in colorectal cancer : Evolving genomic landscape and emerging consensus. In: Future Oncology. 2015 ; Vol. 11, No. 19. pp. 2711-2719.
@article{bf8f7d72725242cdac38e9715edf9fd1,
title = "Precision medicine in colorectal cancer: Evolving genomic landscape and emerging consensus",
abstract = "Colorectal cancer is the third most lethal cancer in men and women in the USA. Although surgical resection is the mainstay of treatment, many patients develop local and widely metastatic disease and become resistant to conventional chemotherapeutics. Recent comprehensive molecular characterization has led to subclassification of colorectal adenocarcinoma based on molecular properties, such as microsatellite instability and high CpG island methylation. These emerging subclassifications are associate with varying frequencies of RAS, BRAF, APC and other genetic events and have the ability to redefine therapeutic regimens. In this review, we examine how molecular diagnostics are currently used while providing insight into emerging implications for molecular analysis for personalized therapy in colorectal cancer.",
keywords = "BRAF, colorectal cancer, KRAS, microsatellite instability, molecular diagnostics, NRAS, personalized medicine",
author = "Fisher, {Kurt W.} and Antonio Lopez-Beltran and Rodolfo Montironi and Liang Cheng",
year = "2015",
month = "10",
day = "1",
doi = "10.2217/fon.15.219",
language = "English (US)",
volume = "11",
pages = "2711--2719",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "19",

}

TY - JOUR

T1 - Precision medicine in colorectal cancer

T2 - Evolving genomic landscape and emerging consensus

AU - Fisher, Kurt W.

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Cheng, Liang

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Colorectal cancer is the third most lethal cancer in men and women in the USA. Although surgical resection is the mainstay of treatment, many patients develop local and widely metastatic disease and become resistant to conventional chemotherapeutics. Recent comprehensive molecular characterization has led to subclassification of colorectal adenocarcinoma based on molecular properties, such as microsatellite instability and high CpG island methylation. These emerging subclassifications are associate with varying frequencies of RAS, BRAF, APC and other genetic events and have the ability to redefine therapeutic regimens. In this review, we examine how molecular diagnostics are currently used while providing insight into emerging implications for molecular analysis for personalized therapy in colorectal cancer.

AB - Colorectal cancer is the third most lethal cancer in men and women in the USA. Although surgical resection is the mainstay of treatment, many patients develop local and widely metastatic disease and become resistant to conventional chemotherapeutics. Recent comprehensive molecular characterization has led to subclassification of colorectal adenocarcinoma based on molecular properties, such as microsatellite instability and high CpG island methylation. These emerging subclassifications are associate with varying frequencies of RAS, BRAF, APC and other genetic events and have the ability to redefine therapeutic regimens. In this review, we examine how molecular diagnostics are currently used while providing insight into emerging implications for molecular analysis for personalized therapy in colorectal cancer.

KW - BRAF

KW - colorectal cancer

KW - KRAS

KW - microsatellite instability

KW - molecular diagnostics

KW - NRAS

KW - personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=84943793195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943793195&partnerID=8YFLogxK

U2 - 10.2217/fon.15.219

DO - 10.2217/fon.15.219

M3 - Article

VL - 11

SP - 2711

EP - 2719

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 19

ER -